{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tb-500-diabetic-neuropathy","title":"TB-500 for Diabetic Neuropathy: Evidence Review","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals slow or misfire. Pain, numbness, and weakness follow. Repair cells struggle to reach the damage sites. Inflammation stays active instead of clearing. The cytoskeleton inside cells that helps them move and rebuild gets disorganized. These layers compound: poor blood flow starves the nerve, stalled inflammation keeps damage going, and failed cell migration prevents rebuilding. The condition persists because breakdown outruns repair.\n\n## Why TB-500 might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your neuropathy involves poor nerve blood supply and slow repair cell movement, the pathways linked to thymosin beta-4 may address those specific steps. TB-500 is a fragment studied for the same actin-binding and migration effects. The framing stays on supporting the repair side rather than suppressing symptoms alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **TB-500** → inflammation clearance / repair-cell migration\n\n## What the evidence actually shows\n\nAll direct data on thymosin beta-4 or TB-500 in diabetic neuropathy comes from animal models. No completed human clinical trials test TB-500 for this condition. (preclinical)\n\n## What scientists say\n\nA 2012 study by Wang and colleagues used db/db mice, a model of type 2 diabetes with peripheral neuropathy. They gave thymosin beta-4 and measured sciatic nerve blood flow, nerve conduction, and responses to touch and heat. Treated mice showed higher functional vessel density, better regional blood flow, improved conduction velocity, and stronger sensory responses compared with untreated diabetic mice. The authors concluded Tβ4 acts on endothelial and Schwann cells to support vascular and nerve recovery. This is one controlled animal experiment. It shows biological activity in this model but does not prove effects or safety in people. (preclinical) A follow-up 2015 paper from the same group examined longer treatment and again reported functional gains in the same mouse model. (preclinical) Later mechanistic papers explored miR-146a and angiopoietin-1 pathways as possible mediators, still in rodents. (mechanistic)\n\n## What people say on Reddit\n\nAnecdotal reports appear in r/Peptides and r/neuropathy. Users describe stacking TB-500 with BPC-157 for peripheral neuropathy symptoms. One thread reported improved ability to stand without support after weeks on the stack. Another mentioned reduced foot pain when combining with other peptides. These are self-reports without controls, lab confirmation, or long-term follow-up. Doses and sources vary. Many note they also manage blood sugar. (anecdotal)\n\n## What people say on X\n\nPublic posts on X mentioning TB-500 and neuropathy are sparse. Most discussions focus on general injury recovery rather than diabetic neuropathy specifically. No large volume of detailed case reports surfaced in recent searches. (anecdotal)\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy trials exist for TB-500 in diabetic neuropathy. Long-term effects on nerve structure in people remain untested. Interactions with common diabetes medications are undocumented. Quality and purity of research-grade or compounded material vary widely. Whether any observed animal benefits translate to measurable clinical outcomes in humans is unknown.\n\n## Safety and limits\n\nThymosin beta-4 fragments have shown good short-term tolerability in the published mouse studies with no obvious toxicity signals. Human safety data for TB-500 itself is limited to small case series in other contexts and remains preliminary. Regulatory status restricts its use in many places. Anyone considering peptides should consult a physician and review current regulations. This article presents research findings only and does not constitute advice.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"A 2012 mouse study found thymosin beta-4 improved sciatic nerve vascular density, blood flow, conduction velocity, and sensory function in db/db diabetic mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the primary animal evidence base for the compound in this condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human clinical trials have tested TB-500 or thymosin beta-4 for diabetic neuropathy.","section":"What we do not know","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap between animal data and human use.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have reported subjective improvements in neuropathy symptoms when stacking TB-500 with BPC-157.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from controlled studies.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Thymosin beta-4 is studied for promoting cell migration via actin regulation and supporting inflammation resolution at injury sites.","section":"Why TB-500 might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Links the compound's studied mechanism directly to the degeneration layers described.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22922221/","title":"Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","summary":"2012 study in db/db mice showing functional recovery with Tβ4.","claim_ids":["c1","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:38:58.954Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"163ffd15cb7fcd1a7bb10bf2d100e99e5d1a44f4d54314cbada1fc79d38c45c5"},{"id":"s2","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"more clinical research is needed before these potential benefits can be considered applicable to humans.","summary":"Notes absence of human trials for neuropathy indications.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:38:58.954Z","link_status":"ok","quote_status":"verified","prev":"163ffd15cb7fcd1a7bb10bf2d100e99e5d1a44f4d54314cbada1fc79d38c45c5","hash":"f0144ddef05a0fe577a5cc71724599ecfd39eb758cf6c9bb12a362a81ca1a11c"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/jtna6y/bpctb4_and_peripheral_neuropathy_results/","title":"BPC+TB4 and peripheral neuropathy results","quote":"Now 1 week to final dose of TB500 he can stand without supporting himself.","summary":"User report of functional improvement on TB-500/BPC stack.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:38:58.954Z","link_status":"ok","quote_status":"unverified","prev":"f0144ddef05a0fe577a5cc71724599ecfd39eb758cf6c9bb12a362a81ca1a11c","hash":"f268a15baf7364fb8f7dccf02f0c8d1afd7628c8ba5257636a289fb9a8301788"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:38:59.835Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Diabetic Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals slow or misfire. Pain, numbness, and weakness follow. Repair cells struggle to reach the damage sites. Inflammation stays active instead of clearing. The cytoskeleton inside cells that helps them move and rebuild gets disorganized. These layers compound: poor blood flow starves the nerve, stalled inflammation keeps damage going, and failed cell migration prevents rebuilding. The condition persists because breakdown outruns repair.\n\n## Why TB-500 might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your neuropathy involves poor nerve blood supply and slow repair cell movement, the pathways linked to thymosin beta-4 may address those specific steps. TB-500 is a fragment studied for the same actin-binding and migration effects. The framing stays on supporting the repair side rather than suppressing symptoms alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **TB-500** → inflammation clearance / repair-cell migration\n\n## What the evidence actually shows\n\nAll direct data on thymosin beta-4 or TB-500 in diabetic neuropathy comes from animal models. No completed human clinical trials test TB-500 for this condition. (preclinical)\n\n## What scientists say\n\nA 2012 study by Wang and colleagues used db/db mice, a model of type 2 diabetes with peripheral neuropathy. They gave thymosin beta-4 and measured sciatic nerve blood flow, nerve conduction, and responses to touch and heat. Treated mice showed higher functional vessel density, better regional blood flow, improved conduction velocity, and stronger sensory responses compared with untreated diabetic mice. The authors concluded Tβ4 acts on endothelial and Schwann cells to support vascular and nerve recovery. This is one controlled animal experiment. It shows biological activity in this model but does not prove effects or safety in people. (preclinical) A follow-up 2015 paper from the same group examined longer treatment and again reported functional gains in the same mouse model. (preclinical) Later mechanistic papers explored miR-146a and angiopoietin-1 pathways as possible mediators, still in rodents. (mechanistic)\n\n## What people say on Reddit\n\nAnecdotal reports appear in r/Peptides and r/neuropathy. Users describe stacking TB-500 with BPC-157 for peripheral neuropathy symptoms. One thread reported improved ability to stand without support after weeks on the stack. Another mentioned reduced foot pain when combining with other peptides. These are self-reports without controls, lab confirmation, or long-term follow-up. Doses and sources vary. Many note they also manage blood sugar. (anecdotal)\n\n## What people say on X\n\nPublic posts on X mentioning TB-500 and neuropathy are sparse. Most discussions focus on general injury recovery rather than diabetic neuropathy specifically. No large volume of detailed case reports surfaced in recent searches. (anecdotal)\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy trials exist for TB-500 in diabetic neuropathy. Long-term effects on nerve structure in people remain untested. Interactions with common diabetes medications are undocumented. Quality and purity of research-grade or compounded material vary widely. Whether any observed animal benefits translate to measurable clinical outcomes in humans is unknown.\n\n## Safety and limits\n\nThymosin beta-4 fragments have shown good short-term tolerability in the published mouse studies with no obvious toxicity signals. Human safety data for TB-500 itself is limited to small case series in other contexts and remains preliminary. Regulatory status restricts its use in many places. Anyone considering peptides should consult a physician and review current regulations. This article presents research findings only and does not constitute advice.","claims":[{"id":"c1","text":"A 2012 mouse study found thymosin beta-4 improved sciatic nerve vascular density, blood flow, conduction velocity, and sensory function in db/db diabetic mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the primary animal evidence base for the compound in this condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human clinical trials have tested TB-500 or thymosin beta-4 for diabetic neuropathy.","section":"What we do not know","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap between animal data and human use.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have reported subjective improvements in neuropathy symptoms when stacking TB-500 with BPC-157.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from controlled studies.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Thymosin beta-4 is studied for promoting cell migration via actin regulation and supporting inflammation resolution at injury sites.","section":"Why TB-500 might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Links the compound's studied mechanism directly to the degeneration layers described.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22922221/","title":"Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"more clinical research is needed before these potential benefits can be considered applicable to humans.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/jtna6y/bpctb4_and_peripheral_neuropathy_results/","title":"BPC+TB4 and peripheral neuropathy results","quote":"Now 1 week to final dose of TB500 he can stand without supporting himself.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14463,"tokens_out":2506,"cost":0.02434375,"prev_hash":"genesis","hash":"7b28c9a15d2222c2eaf26d1a5019c254ad54258c5f55ca66cb1379317f7b51bd"}],"provenance":[{"ts":"2026-06-29T23:38:59.835Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Diabetic Neuropathy\nSlug: tb-500-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"tb-500\",\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathway","response":"{\n  \"slug\": \"tb-500-diabetic-neuropathy\",\n  \"title\": \"TB-500 for Diabetic Neuropathy: Evidence Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals slow or misfire. Pain, numbness, and weakness follow. Repair cells struggle to reach the damage sites. Inflammation stays active instead of clearing. The cytoskeleton inside cells that helps them move and rebuild gets disorganized. These layers compound: poor blood flow starves the nerve, stalled inflammation keeps damage going, and failed cell migration prevents rebuilding. The condition persists because breakdown outruns repair.\\n\\n## Why TB-500 might help you\\n\\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n4. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\nIf your neuropathy involves poor nerve blood supply and slow repair cell movement, the pathways linked to thymosin beta-4 may address those specific steps. TB-500 is a fragment studied for the same actin-binding and migration effects. The framing stays on supporting the repair side rather than suppressing symptoms alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **TB-500** → inflammation clearance / repair-cell migration\\n\\n## What the evidence actually shows\\n\\nAll direct data on thymosin ","tokens_in":14463,"tokens_out":2506,"cost":0,"prev":"genesis","hash":"7ade7cd2082ea148cc2f9ab05080e69d9231b107564e59d9970fcf7af783e060"},{"ts":"2026-07-17T02:42:13.978Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-diabetic-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7ade7cd2082ea148cc2f9ab05080e69d9231b107564e59d9970fcf7af783e060","hash":"6c088f38a58111b56ba8300fbd9a1100a7458db6c24b3e957d622d2c31f52cb6"}],"energy":{"passes":2,"tokens_in":14463,"tokens_out":2506,"tokens_total":16969,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"6c088f38a58111b56ba8300fbd9a1100a7458db6c24b3e957d622d2c31f52cb6"},"posted_at":"2026-06-29T21:33:27.229Z","created_at":"2026-06-29T21:33:27.229Z","updated_at":"2026-07-17T02:42:13.978Z","machine":{"shape":"article.machine/v1","slug":"tb-500-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-diabetic-neuropathy","json":"/api/articles/tb-500-diabetic-neuropathy","markdown":"/api/articles/tb-500-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/tb-500-diabetic-neuropathy/skill","topology":"/api/articles/tb-500-diabetic-neuropathy/topology","versions":"/api/articles/tb-500-diabetic-neuropathy/revisions","invocations":"/api/articles/tb-500-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"567f10b038b8f14d151f33fa418ed9c4448c3e9286388539db7a6e014b49e355","object":{"object_type":"article-object","identity":{"id":"article:tb-500-diabetic-neuropathy","slug":"tb-500-diabetic-neuropathy","title":"TB-500 for Diabetic Neuropathy: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tb-500-diabetic-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tb-500-diabetic-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: tb-500-diabetic-neuropathy\ndescription: Apply the TB-500 for Diabetic Neuropathy: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# TB-500 for Diabetic Neuropathy: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/tb-500-diabetic-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tb-500-diabetic-neuropathy.\n- Read claims and relationships at /api/articles/tb-500-diabetic-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have Diabetic neuropathy Diabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals sl\n\n## Representations\n\n- Human: /a/tb-500-diabetic-neuropathy\n- JSON: /api/articles/tb-500-diabetic-neuropathy\n- Relationships: /api/articles/tb-500-diabetic-neuropathy/topology\n- History: /api/articles/tb-500-diabetic-neuropathy/revisions\n"},"json":{"route":"/api/articles/tb-500-diabetic-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tb-500-diabetic-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tb","500","diabetic","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tb-500-diabetic-neuropathy/invocations?status=success","failure_events":"/api/articles/tb-500-diabetic-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tb-500-diabetic-neuropathy","title":"TB-500 for Diabetic Neuropathy: Evidence Review","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals slow or misfire. Pain, numbness, and weakness follow. Repair cells struggle to reach the damage sites. Inflammation stays active instead of clearing. The cytoskeleton inside cells that helps them move and rebuild gets disorganized. These layers compound: poor blood flow starves the nerve, stalled inflammation keeps damage going, and failed cell migration prevents rebuilding. The condition persists because breakdown outruns repair.\n\n## Why TB-500 might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your neuropathy involves poor nerve blood supply and slow repair cell movement, the pathways linked to thymosin beta-4 may address those specific steps. TB-500 is a fragment studied for the same actin-binding and migration effects. The framing stays on supporting the repair side rather than suppressing symptoms alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **TB-500** → inflammation clearance / repair-cell migration\n\n## What the evidence actually shows\n\nAll direct data on thymosin beta-4 or TB-500 in diabetic neuropathy comes from animal models. No completed human clinical trials test TB-500 for this condition. (preclinical)\n\n## What scientists say\n\nA 2012 study by Wang and colleagues used db/db mice, a model of type 2 diabetes with peripheral neuropathy. They gave thymosin beta-4 and measured sciatic nerve blood flow, nerve conduction, and responses to touch and heat. Treated mice showed higher functional vessel density, better regional blood flow, improved conduction velocity, and stronger sensory responses compared with untreated diabetic mice. The authors concluded Tβ4 acts on endothelial and Schwann cells to support vascular and nerve recovery. This is one controlled animal experiment. It shows biological activity in this model but does not prove effects or safety in people. (preclinical) A follow-up 2015 paper from the same group examined longer treatment and again reported functional gains in the same mouse model. (preclinical) Later mechanistic papers explored miR-146a and angiopoietin-1 pathways as possible mediators, still in rodents. (mechanistic)\n\n## What people say on Reddit\n\nAnecdotal reports appear in r/Peptides and r/neuropathy. Users describe stacking TB-500 with BPC-157 for peripheral neuropathy symptoms. One thread reported improved ability to stand without support after weeks on the stack. Another mentioned reduced foot pain when combining with other peptides. These are self-reports without controls, lab confirmation, or long-term follow-up. Doses and sources vary. Many note they also manage blood sugar. (anecdotal)\n\n## What people say on X\n\nPublic posts on X mentioning TB-500 and neuropathy are sparse. Most discussions focus on general injury recovery rather than diabetic neuropathy specifically. No large volume of detailed case reports surfaced in recent searches. (anecdotal)\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy trials exist for TB-500 in diabetic neuropathy. Long-term effects on nerve structure in people remain untested. Interactions with common diabetes medications are undocumented. Quality and purity of research-grade or compounded material vary widely. Whether any observed animal benefits translate to measurable clinical outcomes in humans is unknown.\n\n## Safety and limits\n\nThymosin beta-4 fragments have shown good short-term tolerability in the published mouse studies with no obvious toxicity signals. Human safety data for TB-500 itself is limited to small case series in other contexts and remains preliminary. Regulatory status restricts its use in many places. Anyone considering peptides should consult a physician and review current regulations. This article presents research findings only and does not constitute advice.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-diabetic-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"A 2012 mouse study found thymosin beta-4 improved sciatic nerve vascular density, blood flow, conduction velocity, and sensory function in db/db diabetic mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the primary animal evidence base for the compound in this condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human clinical trials have tested TB-500 or thymosin beta-4 for diabetic neuropathy.","section":"What we do not know","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap between animal data and human use.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have reported subjective improvements in neuropathy symptoms when stacking TB-500 with BPC-157.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from controlled studies.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Thymosin beta-4 is studied for promoting cell migration via actin regulation and supporting inflammation resolution at injury sites.","section":"Why TB-500 might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Links the compound's studied mechanism directly to the degeneration layers described.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22922221/","title":"Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","summary":"2012 study in db/db mice showing functional recovery with Tβ4.","claim_ids":["c1","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:38:58.954Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"163ffd15cb7fcd1a7bb10bf2d100e99e5d1a44f4d54314cbada1fc79d38c45c5"},{"id":"s2","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"more clinical research is needed before these potential benefits can be considered applicable to humans.","summary":"Notes absence of human trials for neuropathy indications.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:38:58.954Z","link_status":"ok","quote_status":"verified","prev":"163ffd15cb7fcd1a7bb10bf2d100e99e5d1a44f4d54314cbada1fc79d38c45c5","hash":"f0144ddef05a0fe577a5cc71724599ecfd39eb758cf6c9bb12a362a81ca1a11c"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/jtna6y/bpctb4_and_peripheral_neuropathy_results/","title":"BPC+TB4 and peripheral neuropathy results","quote":"Now 1 week to final dose of TB500 he can stand without supporting himself.","summary":"User report of functional improvement on TB-500/BPC stack.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:38:58.954Z","link_status":"ok","quote_status":"unverified","prev":"f0144ddef05a0fe577a5cc71724599ecfd39eb758cf6c9bb12a362a81ca1a11c","hash":"f268a15baf7364fb8f7dccf02f0c8d1afd7628c8ba5257636a289fb9a8301788"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:38:59.835Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Diabetic Neuropathy: Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Diabetic neuropathy\n\nDiabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals slow or misfire. Pain, numbness, and weakness follow. Repair cells struggle to reach the damage sites. Inflammation stays active instead of clearing. The cytoskeleton inside cells that helps them move and rebuild gets disorganized. These layers compound: poor blood flow starves the nerve, stalled inflammation keeps damage going, and failed cell migration prevents rebuilding. The condition persists because breakdown outruns repair.\n\n## Why TB-500 might help you\n\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf your neuropathy involves poor nerve blood supply and slow repair cell movement, the pathways linked to thymosin beta-4 may address those specific steps. TB-500 is a fragment studied for the same actin-binding and migration effects. The framing stays on supporting the repair side rather than suppressing symptoms alone.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **TB-500** → inflammation clearance / repair-cell migration\n\n## What the evidence actually shows\n\nAll direct data on thymosin beta-4 or TB-500 in diabetic neuropathy comes from animal models. No completed human clinical trials test TB-500 for this condition. (preclinical)\n\n## What scientists say\n\nA 2012 study by Wang and colleagues used db/db mice, a model of type 2 diabetes with peripheral neuropathy. They gave thymosin beta-4 and measured sciatic nerve blood flow, nerve conduction, and responses to touch and heat. Treated mice showed higher functional vessel density, better regional blood flow, improved conduction velocity, and stronger sensory responses compared with untreated diabetic mice. The authors concluded Tβ4 acts on endothelial and Schwann cells to support vascular and nerve recovery. This is one controlled animal experiment. It shows biological activity in this model but does not prove effects or safety in people. (preclinical) A follow-up 2015 paper from the same group examined longer treatment and again reported functional gains in the same mouse model. (preclinical) Later mechanistic papers explored miR-146a and angiopoietin-1 pathways as possible mediators, still in rodents. (mechanistic)\n\n## What people say on Reddit\n\nAnecdotal reports appear in r/Peptides and r/neuropathy. Users describe stacking TB-500 with BPC-157 for peripheral neuropathy symptoms. One thread reported improved ability to stand without support after weeks on the stack. Another mentioned reduced foot pain when combining with other peptides. These are self-reports without controls, lab confirmation, or long-term follow-up. Doses and sources vary. Many note they also manage blood sugar. (anecdotal)\n\n## What people say on X\n\nPublic posts on X mentioning TB-500 and neuropathy are sparse. Most discussions focus on general injury recovery rather than diabetic neuropathy specifically. No large volume of detailed case reports surfaced in recent searches. (anecdotal)\n\n## What we do not know\n\nNo human pharmacokinetic or efficacy trials exist for TB-500 in diabetic neuropathy. Long-term effects on nerve structure in people remain untested. Interactions with common diabetes medications are undocumented. Quality and purity of research-grade or compounded material vary widely. Whether any observed animal benefits translate to measurable clinical outcomes in humans is unknown.\n\n## Safety and limits\n\nThymosin beta-4 fragments have shown good short-term tolerability in the published mouse studies with no obvious toxicity signals. Human safety data for TB-500 itself is limited to small case series in other contexts and remains preliminary. Regulatory status restricts its use in many places. Anyone considering peptides should consult a physician and review current regulations. This article presents research findings only and does not constitute advice.","claims":[{"id":"c1","text":"A 2012 mouse study found thymosin beta-4 improved sciatic nerve vascular density, blood flow, conduction velocity, and sensory function in db/db diabetic mice.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes the primary animal evidence base for the compound in this condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human clinical trials have tested TB-500 or thymosin beta-4 for diabetic neuropathy.","section":"What we do not know","tier":"mechanistic","source_ids":["s2"],"source_status":"sourced","why_material":"Clarifies the evidence gap between animal data and human use.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have reported subjective improvements in neuropathy symptoms when stacking TB-500 with BPC-157.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s3"],"source_status":"sourced","why_material":"Captures real-world user experience separate from controlled studies.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Thymosin beta-4 is studied for promoting cell migration via actin regulation and supporting inflammation resolution at injury sites.","section":"Why TB-500 might help you","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Links the compound's studied mechanism directly to the degeneration layers described.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:59.444Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22922221/","title":"Thymosin β4 promotes the recovery of peripheral neuropathy in type II diabetic mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"more clinical research is needed before these potential benefits can be considered applicable to humans.","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/jtna6y/bpctb4_and_peripheral_neuropathy_results/","title":"BPC+TB4 and peripheral neuropathy results","quote":"Now 1 week to final dose of TB500 he can stand without supporting himself.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":14463,"tokens_out":2506,"cost":0.02434375,"prev_hash":"genesis","hash":"7b28c9a15d2222c2eaf26d1a5019c254ad54258c5f55ca66cb1379317f7b51bd"}],"provenance":[{"ts":"2026-06-29T23:38:59.835Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Diabetic Neuropathy\nSlug: tb-500-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"tb-500\",\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathway","response":"{\n  \"slug\": \"tb-500-diabetic-neuropathy\",\n  \"title\": \"TB-500 for Diabetic Neuropathy: Evidence Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy develops when high blood sugar damages nerves over time. Small blood vessels that feed the nerves narrow or leak. Nerve fibers lose their protective myelin. Signals slow or misfire. Pain, numbness, and weakness follow. Repair cells struggle to reach the damage sites. Inflammation stays active instead of clearing. The cytoskeleton inside cells that helps them move and rebuild gets disorganized. These layers compound: poor blood flow starves the nerve, stalled inflammation keeps damage going, and failed cell migration prevents rebuilding. The condition persists because breakdown outruns repair.\\n\\n## Why TB-500 might help you\\n\\n1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n3. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n4. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\nIf your neuropathy involves poor nerve blood supply and slow repair cell movement, the pathways linked to thymosin beta-4 may address those specific steps. TB-500 is a fragment studied for the same actin-binding and migration effects. The framing stays on supporting the repair side rather than suppressing symptoms alone.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **TB-500** → inflammation clearance / repair-cell migration\\n\\n## What the evidence actually shows\\n\\nAll direct data on thymosin ","tokens_in":14463,"tokens_out":2506,"cost":0,"prev":"genesis","hash":"7ade7cd2082ea148cc2f9ab05080e69d9231b107564e59d9970fcf7af783e060"},{"ts":"2026-07-17T02:42:13.978Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-diabetic-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7ade7cd2082ea148cc2f9ab05080e69d9231b107564e59d9970fcf7af783e060","hash":"6c088f38a58111b56ba8300fbd9a1100a7458db6c24b3e957d622d2c31f52cb6"}],"energy":{"passes":2,"tokens_in":14463,"tokens_out":2506,"tokens_total":16969,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"6c088f38a58111b56ba8300fbd9a1100a7458db6c24b3e957d622d2c31f52cb6"},"posted_at":"2026-06-29T21:33:27.229Z","created_at":"2026-06-29T21:33:27.229Z","updated_at":"2026-07-17T02:42:13.978Z","machine":{"shape":"article.machine/v1","slug":"tb-500-diabetic-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-diabetic-neuropathy","json":"https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy","bundle":"https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-diabetic-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-diabetic-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-diabetic-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-diabetic-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-diabetic-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-diabetic-neuropathy","json":"/api/articles/tb-500-diabetic-neuropathy","markdown":"/api/articles/tb-500-diabetic-neuropathy/bundle?format=markdown","skill":"/api/articles/tb-500-diabetic-neuropathy/skill","topology":"/api/articles/tb-500-diabetic-neuropathy/topology","versions":"/api/articles/tb-500-diabetic-neuropathy/revisions","invocations":"/api/articles/tb-500-diabetic-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-diabetic-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"567f10b038b8f14d151f33fa418ed9c4448c3e9286388539db7a6e014b49e355"}}}